Leukemia: Clinical Trials

43 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 unknown. 43 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 443Unknown 43

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 43 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
25(OH)D3, vitamin D3 - Multiple Sclerosis, Relapsing-Remitting, Adult ALL
Phase 4UnknownTehran University of Medical Sciences542022-07-012022-04-22
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity
Phase 4UnknownHospital General de Mexico562021-12-122022-01-18
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase
Phase 4UnknownJiangsu Hansoh Pharmaceutical Co., Ltd.2002021-11-232022-04-29
Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia
Simvastatin - Strains, Acute Lymphoblastic Leukemia
Phase 4UnknownHospital General de Mexico1082021-11-192022-01-04
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase
Phase 4UnknownShenzhen Second People's Hospital2002021-01-012022-03-16
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Dasatinib - Dasatinib, BCR-ABL
Phase 4UnknownShenzhen Second People's Hospital652019-12-012022-07-27
Ikervis for DED Due to GVHD Post Allo-HSCT
Cyclosporine Ophthalmic - Leukemia (Both ALL and AML), MDS-EB-1
Phase 4UnknownSingapore Eye Research Institute402019-11-282020-11-19
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Azacytidine, HAG Regimen, Azacytidine - Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
Phase 4UnknownShenzhen Second People's Hospital1142019-09-012022-03-15
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
CODOX-M/IVAC, Decitabine - T-lymphoblastic Lymphoma
Phase 4UnknownMingzhi Zhang402018-06-012018-09-14
Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine - Acute Myeloid Leukemia
Phase 4UnknownThe First Hospital of Jilin University1802017-01-012017-01-20
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
Imatinib, Nilotinib - Chronyc Myeloid Leukemia
Phase 4UnknownGruppo Italiano Malattie EMatologiche dell'Adulto4502016-11-112022-01-20
ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
Anti-human Thymoglobulin, Placebo - Lymphoblastic Lymphoma
Phase 4UnknownShanghai General Hospital, Shanghai Jiao Tong University School of Medicine1302016-10-012016-10-25
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
GM-CSF, G-CSF, GM-CSF and G-CSF - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 4UnknownXinhua Hospital, Shanghai Jiao Tong University School of Medicine4052016-09-272018-10-17
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd), Cytarabine(Actavis Italy S.p.A), Fludarabine (Bayer) - Leukemia
Phase 4UnknownChinese PLA General Hospital802016-07-012016-05-27
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Dasatinib 50 MG - Chronic Myelogenous Leukemia
Phase 4UnknownHospital Universitario Dr. Jose E. Gonzalez122016-04-012017-07-13
Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Nilotinib - Leukemia, Chronic Myeloid
Phase 4UnknownSamsung Medical Center402015-04-012015-03-17
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
Aprepitant - Leukemia, Lymphoma
Phase 4UnknownSun Yat-sen University852015-04-012015-01-27
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Imatinib - Chronic Myeloid Leukemia
Phase 4UnknownCttq902015-02-012014-12-15
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy
Mercaptopurine - Acute Lymphoblastic Leukemia
Phase 4UnknownShandong University5002015-01-012019-04-23
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Interferon-alpha - Acute Myeloid Leukemia
Phase 4UnknownPeking University People's Hospital402013-10-012016-09-29

Showing 20 of 43. Sign in to see all of them.

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (17)  ·  Leukemia, Myeloid, Acute (11)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6)  ·  Recurrence (4)  ·  Leukemia, Promyelocytic, Acute (3)  ·  Leukemia, Myeloid, Chronic-Phase (2)  ·  Lymphoma (2)  ·  Myelodysplastic Syndromes (2)  ·  Dwarfism (1)  ·  Febrile Neutropenia (1)  ·  Hepatoblastoma (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)

Broader conditions

Hematologic Diseases (43)  ·  Hemic and Lymphatic Diseases (43)  ·  Neoplasms by Histologic Type (43)  ·  Neoplasms (42)  ·  Leukemia, Myeloid (23)  ·  Lymphatic Diseases (20)  ·  Lymphoproliferative Disorders (20)  ·  Immune System Diseases (19)  ·  Immunoproliferative Disorders (19)  ·  Leukemia, Lymphoid (18)  ·  Pathologic Processes (15)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Disease Attributes (13)  ·  Bone Marrow Diseases (10)

Interventions

Cytarabine (11)  ·  Idarubicin (8)  ·  Cyclophosphamide (5)  ·  Dexamethasone (4)  ·  Granulocyte Colony-Stimulating Factor (4)  ·  Mercaptopurine (4)  ·  Methotrexate (4)  ·  Vincristine (4)  ·  fludarabine (4)  ·  Daunorubicin (3)  ·  Decitabine (3)  ·  Imatinib Mesylate (3)  ·  Arsenic Trioxide (2)  ·  Busulfan (2)  ·  Dasatinib (2)

Sponsors

Shenzhen Second People's Hospital (3)  ·  Hospital General de Mexico (2)  ·  PETHEMA Foundation (2)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2)  ·  Sun Yat-sen University (2)  ·  Changhai Hospital (1)  ·  Chinese Academy of Medical Sciences (1)  ·  Chinese PLA General Hospital (1)  ·  Cttq (1)  ·  East Valley Hematology and Oncology Medical Group (1)  ·  German AML Cooperative Group (1)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  Guangdong Provincial People's Hospital (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)

Countries

China (16)  ·  Germany (3)  ·  Mexico (3)  ·  Denmark (2)  ·  Italy (2)  ·  Singapore (2)  ·  Spain (2)  ·  India (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  Russia (1)  ·  Switzerland (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Adolfo Martinez Tovar, PhD (2)  ·  Ajay Vora (1)  ·  Allen Yeoh, MBBS (1)  ·  Changgang Li, M.D. (1)  ·  Christina Peters, Prof. MD PhD (1)  ·  Daihong Liu, Doctor (1)  ·  Dongbo Lai, M.D. (1)  ·  Eva Lengfelder, MD, PhD (1)  ·  Fabrizio Pane (1)  ·  Fang Yongjun, Ph.D (1)  ·  Franco Locatelli, Prof. MD PhD (1)  ·  Gao Fei, Ph.D (1)  ·  Gerhard Ehninger, MD (1)  ·  Giovanni Martinelli, MD (1)

Results publications

PMID 10231138, PMID 10583235, PMID 11863096, PMID 12627513, PMID 14585365, PMID 16110027, PMID 16197446, PMID 17410187, PMID 18398750, PMID 18626005, PMID 19167677, PMID 19822296, PMID 19951974, PMID 20542125, PMID 20625136, PMID 22318524, PMID 22512017, PMID 22677206, PMID 22871557, PMID 22966847, PMID 23376821, PMID 23383989, PMID 25314773, PMID 25528350, PMID 26230956, PMID 28116786, PMID 29250743, PMID 30044693, PMID 30076280, PMID 30872105, PMID 30957229, PMID 32519032, PMID 33495363, PMID 35154096, PMID 35714315, PMID 36856978, PMID 37276496, PMID 3896457, PMID 7581076

NIH funding

2005 (1)